The current stock price of TKNO is 3.955 USD. In the past month the price decreased by -14.95%. In the past year, price decreased by -53.72%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 25.93 | 218.19B | ||
| DHR | DANAHER CORP | 29.89 | 162.76B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 185.51 | 56.37B | ||
| A | AGILENT TECHNOLOGIES INC | 24.72 | 39.11B | ||
| IQV | IQVIA HOLDINGS INC | 19.39 | 38.40B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 33.92 | 29.00B | ||
| WAT | WATERS CORP | 30.31 | 22.91B | ||
| ILMN | ILLUMINA INC | 30.73 | 20.47B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 38.82 | 19.75B | ||
| MEDP | MEDPACE HOLDINGS INC | 39.81 | 16.04B | ||
| TEM | TEMPUS AI INC | N/A | 10.97B | ||
| RVTY | REVVITY INC | 20.19 | 10.96B |
Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. The company is headquartered in Hollister, California and currently employs 173 full-time employees. The company went IPO on 2021-06-25. The company offers two primary product categories, which include lab essentials and clinical solutions. The company also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The firm offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. The company supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and others, with catalog and custom, made-to-order products.
ALPHA TEKNOVA INC
2451 Bert Drive
Hollister CALIFORNIA US
CEO: Stephen Gunstream
Employees: 173
Phone: 18316371100
Alpha Teknova, Inc. engages in the manufacture of cell culture media and supplements. The company is headquartered in Hollister, California and currently employs 173 full-time employees. The company went IPO on 2021-06-25. The company offers two primary product categories, which include lab essentials and clinical solutions. The company also offers three primary product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. The firm offers its liquid cell culture media and supplements and molecular biology reagents in both of its two product categories; pre-poured media plates are available in its Lab Essentials category only. The company supports customers spanning the life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and others, with catalog and custom, made-to-order products.
The current stock price of TKNO is 3.955 USD. The price decreased by -2.1% in the last trading session.
TKNO does not pay a dividend.
TKNO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
ALPHA TEKNOVA INC (TKNO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.35).
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on TKNO.
ALPHA TEKNOVA INC (TKNO) has a market capitalization of 211.71M USD. This makes TKNO a Micro Cap stock.
ChartMill assigns a fundamental rating of 2 / 10 to TKNO. TKNO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months TKNO reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS increased by 49.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.93% | ||
| ROE | -25.08% | ||
| Debt/Equity | 0.18 |
12 analysts have analysed TKNO and the average price target is 9.18 USD. This implies a price increase of 132.11% is expected in the next year compared to the current price of 3.955.
For the next year, analysts expect an EPS growth of 42.95% and a revenue growth 8.18% for TKNO